SCHEMBL223822

SCHEMBL223822

CCc1ccc(Br)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2767496 0.86 KDM4E (0.38)
SCHEMBL2767967 0.84 DPP4 (0.38)
SCHEMBL225342 0.80
SCHEMBL45854 0.80
SCHEMBL155145 0.78 TDP1 (0.40)
SCHEMBL1414863 0.78 KDM4E (0.45)
SCHEMBL13049960 0.78 KDM4E (0.45)
SCHEMBL3870601 0.77 KDM4E (0.42)
SCHEMBL13873989 0.76
SCHEMBL1522719 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112920813-B Photo-thermal response chiral photosensitive liquid crystal dopant containing azobenzene binaphthyl 湘潭大学 2023-08-22 CN claimed
CN-112920813-A Photo-thermal responsive chiral photosensitive liquid crystal dopant containing azobenzene binaphthalene 湘潭大学 2021-06-08 CN claimed
CN-102574857-B Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors LEO PHARMA AS 2015-06-10 CN claimed
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMA INC (US) 2026-03-05 US disclosed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
WO-2023205701-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-10-26 WO disclosed
US-20230295137-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA FARBER CANCER INST INC (US) 2023-09-21 US disclosed
CN-112920813-B Photo-thermal response chiral photosensitive liquid crystal dopant containing azobenzene binaphthyl 湘潭大学 2023-08-22 CN disclosed
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 US disclosed
US-7169786-B2 Isoxazoline derivatives as anti-depressants JANSSEN-CILAG S.A. (ES) 2007-01-30 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20050153167-A1 repeating units of arylene groups, divalent heterocyclic groups and divalent aromatic amine groups, and end group(s) of, a monovalent heterocyclic group optionally coordinated to form a metal complex, and an aromatic end group, fluorescence in the solid state, high molecular weight, excellent properties SUMITOMO CHEMICAL COMPANY, LIMITED 2005-07-14 US disclosed
CN-1164574-C Phenoxypropylamine compounds ������ҩ��ʽ���� 2004-09-01 CN disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
CN-1378533-A Phenoxypropylamine compounds MITSUBISHI PHARMACEUTICAL CO L (JP) 2002-11-06 CN disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed